Target family: Hydrolases & Lipases (type: enzyme)
Target: epoxide hydrolase 2

Ligand: AR-9281 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Published in: Bioorg Med Chem Lett

Ligand: AR-9281 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.770000457763672 pIC50
Reference (Journal): Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
Published in: Eur J Med Chem

Ligand: AR-9281 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: <i>In Vivo</i> Evaluation in a Murine Model of Acute Pancreatitis.
Published in: J Med Chem

Ligand: BI-1935 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase.
Published in: Bioorg Med Chem Lett

Ligand: compound G1 [PMID: 36689364] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.850000381469727 pIC50
Reference (Journal): Structure-Directed Discovery of Potent Soluble Epoxide Hydrolase Inhibitors for the Treatment of Inflammatory Diseases.
Published in: J Med Chem

Ligand: compound G1 [PMID: 36689364] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.300000190734863 pIC50
Reference (Journal): Structure-Directed Discovery of Potent Soluble Epoxide Hydrolase Inhibitors for the Treatment of Inflammatory Diseases.
Published in: J Med Chem

Ligand: diflapolin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase.
Published in: Sci Rep

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Patent): Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah)

Ligand: EC5026 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.300000190734863 pKi
Reference (Journal): Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
Published in: J Med Chem

Ligand: GSK2256294 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.960000038146973 pIC50
Reference (Journal): Design and synthesis of fused soluble epoxide hydrolase/peroxisome proliferator-activated receptor modulators
Published in: Medchemcomm

Ligand: inhibitor M9 [PMID: 38236416] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.140000343322754 pIC50
Reference (Journal): Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality.
Published in: J Med Chem

Ligand: inhibitor M9 [PMID: 38236416] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Design and Synthesis of Dual-Targeting Inhibitors of sEH and HDAC6 for the Treatment of Neuropathic Pain and Lipopolysaccharide-Induced Mortality.
Published in: J Med Chem

Ligand: MPPA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.680000305175781 pIC50
Reference (Journal): Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
Published in: J Med Chem

Ligand: MPPA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.820000171661377 pIC50
Reference (Journal): Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
Published in: J Med Chem

Ligand: oxaprozin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1992)
Primary target: no
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Bacterial Expression and HTS Assessment of Soluble Epoxide Hydrolase Phosphatase.
Published in: J Biomol Screen

Ligand: PF750 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: SMTP-7 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Use of inhibitors of phosphatase activity of soluble epoxide for the treatment of cardiometabolic diseases

Ligand: SWE101 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
Published in: J Med Chem

Ligand: SWE101 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pKd
Reference (Journal): Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain.
Published in: J Med Chem

Ligand: triple modulator 10 [PMID: 29878767] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.369999885559082 pIC50
Reference (Journal): Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.
Published in: J Med Chem

Ligand: zafirlukast (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.
Published in: J Med Chem